Skip to Content
Merck
All Photos(1)

Key Documents

1719000

USP

Warfarin

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin, Coumafene

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C19H16O4
CAS Number:
Molecular Weight:
308.33
Beilstein:
8868198
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

warfarin

manufacturer/tradename

USP

mp

162-164 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O

InChI

1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

InChI key

PJVWKTKQMONHTI-UHFFFAOYSA-N

Gene Information

human ... VKORC1(79001)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Warfarin USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Warfarin Sodium
  • Warfarin Sodium Tablets
  • Warfarin Sodium for Injection

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Legal Information

Signal Word

Danger

Hazard Classifications

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral

Target Organs

Blood

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 4

1 of 4

Daisuke Yoshioka et al.
Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 17(4), 308-314 (2014-07-23)
The aim of this study was to evaluate our clinical experience with the Jarvik 2000 axial flow pump (Jarvik Heart, Inc, New York, NY, USA), a miniature axial flow left ventricular assist device (LVAD). The clinical results of eight patients
James D Douketis et al.
Thrombosis and haemostasis, 113(3), 625-632 (2014-12-05)
In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of perioperative bridging anticoagulation is uncertain.We accessed the database from RE-LY, a randomised trial comparing dabigatran with warfarin for
Benjamin A Steinberg et al.
Circulation, 131(5), 488-494 (2014-12-17)
Temporary interruption of oral anticoagulation for procedures is often required, and some propose using bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions in clinical practice are unknown. The Outcomes Registry for Better Informed Treatment of
Hugh S Markus et al.
The Lancet. Neurology, 14(4), 361-367 (2015-02-17)
Extracranial carotid and vertebral artery dissection is an important cause of stroke, especially in young people. In some observational studies it has been associated with a high risk of recurrent stroke. Both antiplatelet drugs and anticoagulant drugs are used to
Tomasz Baron et al.
Heart (British Cardiac Society), 101(2), 101-106 (2014-10-22)
We aimed to assess differences in incidence, clinical features, current treatment strategies and outcome in patients with type 2 vs. type 1 acute myocardial infarction (AMI). All 20 138 hospitalisations in Sweden with a diagnosis of AMI registered during 2011 in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service